teaser
Macmillan Cancer Support has published a new report praising the Cancer Drugs Fund for improving access to vital medicines for cancer patients.
However, the report bemoans the lack of plans to ensure that cancer patients will continue to receive treatment once the Fund ends in 2014 and a new Value-Based Pricing System is introduced.
Mike Hobday, Senior Public Affairs Officer at Macmillan, who co-wrote the report, said:
